Wednesday, July 28, 2010

Hemaquest Raises $4M

Seattle-based HemaQuest Pharmaceuticals, a firm developing small molecule therapeutic treatments for sickle cell disease, beta thalassemia, and cancer, said today that it has raised and additional $4M in its Series B round, bringing the total in the round to $16M. The new investment was led by Latterell Venture Partners. Other investors in the firm are Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures. As part of the new funding, the company said that Latterell's James Woody has joined its board of directors. The new funding will go to help advance the firm's two lead products through Phase 2b clinical trials. More information »